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Background 
 
The question of why the attitudes towards economic evaluation in health care differ so 
much from one jurisdiction to another has long been a source of discussion among 
scholars. Differences are observed both in whether economic evaluation plays a 
significant role in decision-making and the methods employed. In some countries, 
such as The Netherlands, Sweden and the United Kingdom, the use of economic 
evaluation is extensive and focuses on the quality-adjusted life-year (QALY) as a 
measure of health gain. However, in Germany and the United States, the use of 
economic evaluation is limited and QALYs are not favoured. In commenting on the 
use of economic evaluation, within the broader activity of health technology 
assessment (HTA) by the National Institute for Health and Care Excellence (NICE) in 
the United Kingdom (UK), Le Pen (2009) noted that there may be two reasons why 
similar bodies on the continent of Europe, such as HAS in France and IQWiG in 
Germany, might adopt a different approach. [1] First, there are classical distinctions 
between NHS-EDVHGµ%HYHULGJe¶V\VWHPVDQGVRFLDOinsurance-EDVHGµ%LVPDUFN¶
health care systems. Secondly, they may be more philosophical differences relating to 
concepts of illness, health and medicine that cause continental countries to reject the 
µ$QJOR-6D[RQ¶PHWKRGVRIDVVHVsing health care. 
 
The differences between Beveridge and Bismarck systems have been extensively 
investigated. Or et al (2010) argue that Beveridge-type systems are based on the 
underlying values of universality and equity, whereas Bismarck-type systems are 
based on the values of plurality, liberty and solidarity. [2] Therefore, it should come 
as no surprise that in the UK, which has a Beveridge-type system, there is universal 
coverage but relatively little consumer choice in the services offered. In contrast, in 
Germany, which has a Bismarck-type system, there is a plurality of providers and an 
abundance of choice, with the consequence that some individuals may be treated 
differently from others. $VLPLODUGLFKRWRP\RIYDOXHVXQGHUSLQVWKH2(&'¶V
typology of health care systems.  At the one end of the spectrum, national health 
services, like those existing in the UK, Italy and several Scandinavian countries, are 
based on a strong notion of social equity. At the other end of the spectrum private 
insurance systems, like that existing in the US, are based on a strong notion of patient 
sovereignty. Social insurance systems, like those existing in France and Germany, lie 
somewhere in between.  
 
Not only do the underpinning values and culture have an influence on healthcare 
systems, but the institutional context may have an important role as well. The public 
administration literature examines institutional contexts and considers the influence of 
administrative traditions in the shaping of healthcare systems. Peters (2008) defines 
WKHQRWLRQRIDGPLQLVWUDWLYHWUDGLWLRQDVµDQKLVWRULFDOO\EDVHGVHWRIYDOXHVVWUXFWXUHV
and relationships with other institutions that defines the nature of appropriate public 
administratiRQZLWKLQVRFLHW\¶ [3] The OLWHUDWXUHVXJJHVWVWKDW³FOXVWHUV´RIFRXQWULHV
may have developed a tradition of public administration because of historical reasons: 
typical clusters often considered are the Anglo-American countries, the Nordic 
European countries, and, to a lesser extent, the Germanic countries in addition to 
Napoleonic countries. [4] 
 In a paper discussing the Napoleonic administrative tradition in countries such as 
France, Greece, Italy, Portugal and Spain, Peters (2008) develops several dimensions 
along which the Napoleonic tradition can be defined and compared with alternative 
approaches. These are: the relationship of the state to society, the relative weight of 
management and the law in defining the fundamental tasks of administration, the 
relationships between politics (politicians) and administration (civil servants), the 
conception of the civil service, the relative value given to the other. Typically, a law 
has to be passed before public officials implement a new policy.[3] In contrast, the 
Anglo-American administrative tradition allows public officials much more freedom 
to implement policies. In addition, this tradition encourages more transparency and 
involvement of key stakeholders in the decision-making process [5] 
These differences suggest that the administrative tradition could have an influence 
both over the governance of bodies practising HTA and the level of transparency in 
approach. 
 
The influence of culture, values and institutional context on the use of economic 
evaluation has recently been studied in more depth. [6] Our research considered the 
factors driving the use of economic evaluation, as part of health technology 
assessment, in the 5 largest EU countries,.  The starting premise was that countries do 
not end up with a particular form of health care system, or approach to economic 
evaluation, by accident. Often these are a product of the underlying culture, values 
and institutional history of the country concerned. These influences can impact on the 
use of economic evaluation directly, or indirectly by how they shape the health care 
system. 
 
The study built on the analysis performed by Landwehr and Kinnert (2014), who 
investigated social values in healthcare systems in France, Germany and UK and 
concluded that these three countries significantly differ in attitudes toward efficiency, 
equity and personal responsibility criteria. [7] According to their analysis, the French 
system can be characterized as focusing strongly on need ± but not on efficiency. In 
contrast, equality seems to play a role on a rather abstract, constitutional level 
whereas personal responsibility for health seems to play no role at all. In German 
institutions, efficiency and personal responsibility are embraced by the legislator at an 
abstract level, while the British system expresses a strong concern for efficiency and 
equality, while the principle of personal responsibility for health is explicitly rejected 
[7] 
 
Unfortunately, there are no similar empirical investigations on social values 
underpinning Italian and Spanish healthcare institutions, but a few considerations can 
be identified on the basis of current literature. The constitutions of both countries 
grant substantial powers to the regions, but at the same time clearly identify national 
rights, including that of access to healthcare. Within this institutional context, equity 
emerges as a predominant social value with increasing concern on efficiency in the 
past decade. In both countries, personal responsibility has not entered the policy 
debate as a criterion to ration scarce resources. [8] [9] 
Can an understanding of the differences in culture, values and administrative tradition 
help us predict how economic evaluation might be used in a given country? In our 
study we attempted to shed some light on this inquiry by examining three dimensions  
(i) the organization and governance of the agencies undertaking HTA and economic 
evaluation, (ii) the methods of economic evaluation used and (iii) the use of HTA and 
economic evaluation in decision-making.  
Organisation and governance of HTA and economic evaluation 
With respect to organization and governance, all largest five European countries have 
established agencies to conduct HTA, such as the HAS in France, IQWiG in Germany 
and NICE in the UK (specifically England). The influence of culture and values on 
the establishment of the various bodies does not appear to be strong, except that in the 
UK the main motivation for establishing NICE was the need for equity in access to 
KHDOWKFDUH7KHJRYHUQPHQWZDVFRQFHUQHGDERXWWKHH[LVWHQFHRIµSRVWFRGH
rationing¶ZKHUHE\LQGLYLGXDOVLQVRPHORFDWLRQVKDGDFFHVVWRQHZDQGH[SHQVLYH
health technologies, but those in other locations did not. It was hoped that NICE 
would remove these inequalities, although since it was established it has pursued a 
strong efficiency agenda, consistent with the fixed budget for health care in the UK 
National Health Service. 
On the other hand, the institutional tradition does appear to have had an influence 
over the various HTA agencies. NICE is a statutory independent agency that has 
considerable control over its own organization and rules of procedure. It has been 
GHSLFWHGDVWKHW\SLFDOH[DPSOHRI³UHJXODWLRQE\GHOHJDWLRQ´ZKLFKLVDSDUWLFXODU
characteristic of the British public service tradition [10] 
Spain and Italy also have Beveridge-type systems and, together with the UK, exhibit a 
high level of delegation, but show a lesser degree of independence from the 
government. This is explained by the fact that these two countries still follow the 
Napoleonic tradition, whereby public choices are delegated but remain an internal 
governmental issue. This is also illustrated by the lower involvement of stakeholders 
in the assessment process as compared with UK, which makes Italian and Spanish 
Agencies almost exclusively (directly or indirectly) accountable only to the 
government (and not to other stakeholders). The exception is National Drug Agency -
AIFA in Italy, which benefits from a higher degree of independence than its recently 
introduced counterpart for medical devices, the Cabina di Regia (Steering 
Committee)[11].  This occurred because of institutional reasons: AIFA was 
established after an extended period of bribery and scandals involving the central 
government, with regard to the reimbursement of pharmaceuticals. In this case, lack 
of credibility and political uncertainty underpinned the decision to delegate regulatory 
and decision±making powers so to depoliticize the process. Moreover, AIFA was 
meant to unify under one single agency the entire regulatory process of market access 
of drugs.[12] (Fattore and Jommi 2008). 
In Germany rationing and priority setting are not generally accepted topics, which is 
demonstrated by the fact that Germany is a rare example of an OECD country without 
a positive list for drugs.  [10] This is also why in Germany the level of delegation is 
very high. In 2010 the German parliament passed the reform that completely revises 
pricing regulations for newly authorized pharmaceuticals and their reimbursement by 
statutory health insurance providers. The reform also assigns a key responsibility to 
the Federal Joint Committee (G-BA) and the Institute for Quality and Efficiency in 
Health Care (IQWiG), that of conducting benefit assessments of newly authorized 
pharmaceuticals. IQWiG is a statutory independent body with its own budget and 
secretariat, but the degree of independence is less strong than NICE in UK. For 
example, its recommendations regarding new technologies are not binding on the 
health care system. [10] While the main focus is on clinical benefit assessment, 
Germany apparently uses the efficiency principle (but not economic evaluation) to 
guide the rationing process. The efficiency principle is based on the assessment of 
trade-off between costs and benefits and identifies the interventions that provide the 
most value for any given level of investment within a therapeutic area. However, this 
approach is not very transparent, and has a relatively low level of stakeholder 
involvement i the decision-making process [13]  
France follows the Bismarck model and adheres to the principles of universality, 
equality and solidarity. However, it is not clear how these principles actually guide 
the French rationing process, although it is very clear that it is not guided by the 
efficiency principle. The HAS operates according to the principle of need, measured 
in terms of the severity of the illness, effectiveness of the technology and relevance 
for public health. Consistent with the Napoleonic tradition, France has delegated the 
decision-making power but has retained a substantial level of control over it.  
Although funded by multiple sources, HAS has a rather low level of inclusiveness of 
stakeholders. Representatives of the ministry, the sickness funds and the industry may 
take part in the meetings, but have no voting rights; only the expert clinicians, 
appointed by HAS, have the right to vote in the commission when the latter makes the 
final recommendation on the added medical value of the technology, which 
determines its likely price. HAS appears to be more open to stakeholders, in the case 
of patient associations accredited by the Council of State. This may be due to a 
greater awareness of the final binding impact of HAS assessments on the list of 
services covered by WKHLQVXUDQFHV¶XQLRQ81&$0[13]  
Methods of economic evaluation used 
Turning to the methods of economic evaluation, the use of QALYs and cost-utility 
analysis (CUA) is consistent with the social values that underpin the whole 
technology assessment process in Beveridge systems. In the UK, there is a hard 
budget constraint and hence a concern about the opportunity cost, in the displacement 
of existing services, of adopting a new therapy. The use of CUA with an explicit 
decision-making threshold is best suited for taking account of the opportunity cost, 
since the threshold is intended to represent the value of the services that would be 
displaced. Also, consistent with the equity principle adhered to in the UK, all QALYs 
DUHYDOXHGWKHVDPHLUUHVSHFWLYHRIZKRUHFHLYHVWKHPZLWKDQH[FHSWLRQIRUµHQG-of-
OLIH¶WUHDWPHQWVDQGWKHYDOXHVLQWKHIDYRXUHGLQVWUXPHQWWRHVWLPDWH4$/<VFRPH
from a survey of the general population [14-16]. The process is also transparent and 
involves the participation of a number of stakeholder groups, consistent with the 
Anglo-American administrative tradition.  
In contrast, in Germany IQWiG explicitly rejects QALYs, as well as any form of 
comparative assessment across disease areas. The argument, which is also embedded 
in the dignity clause of article 1 of the German constitution, is that the equity 
SULQFLSOHHPEHGGHGLQ4$/<VHTXDOWUHDWPHQWRIHTXDOVµKRUL]RQWDOHTXLW\¶LVOHVV
important than positive discrimination across individuals and/or disease areas 
according to specific needs or other factors (i.e. unequal treatment of unequal or 
µYHUWLFDOHTXLW\¶+RZHYHUKRUL]RQWDOHTXLW\VWLOOSOD\VDPDMRUUROHDQGHfficiency 
can be achieved within WKHVDPHWKHUDSHXWLFDUHDE\HVWLPDWLQJWKHµHIILFLHQF\
IURQWLHU¶,QWHUYHQWLRQVWKDWDUHQRWRQWKHIURQWLHUDUHOHVVGHVLUDEOHEHFDXVHWKH\
produce the same or less benefits at a higher cost than other existing interventions. 
[17] The efficiency frontier is defined within a single therapeutic area and thus does 
not allow comparisons across different disease areas. An important reason for 
IRFXVLQJRQDVLQJOHWKHUDSHXWLFDUHDLVWKDW*HUPDQ\¶VKHDOWKFDUHV\VWHPLVQRW
bound to a fixed national budget and therefore should not consider funding priorities 
across therapeutic areas. In a nutshell, this approach takes existing interventions as the 
norm (efficient) and then judges new ones relative to it. It is very difficult and time 
consuming to construct these efficiency frontiers for each relevant therapeutic area.  
 
However, there is no explicit budget constraint and the use of economic evaluation is 
QRWPDQGDWRU\,QGHHGWKHPDLQDVVHVVPHQWPDGHLVRQHRIµFOLQLFDODGGHGEHQHILW¶
on a scale from 0-5. This lack of the explicit use of efficiency assessment is consistent 
ZLWKWKHYDOXHVXQGHUO\LQJµ%LVParck-W\SH¶KHDOWKFDUHV\VWHPVIn France, Italy and 
Spain the use of economic evaluation is also not mandatory and no method of 
economic evaluation is explicitly preferred. Italy and Spain have the same model of 
National Health Service and a budget constraint as in the UK but they do not have the 
same approach to economic evaluation. This is partly explained by the existence of 
the Napoleonic administrative tradition, which has slowed down the development of 
the procedures for technology assessment policies, owing to the need to establish a 
legal basis and the lower propensity of public officials to act without the appropriate 
legal basis. In addition, regionalization may have had an influence, by softening the 
impact of national budget constraints and spreading the available resources for HTA 
across several regional agencies, rather than concentrating them nationally [18] The 
recently adopted programme for HTA for medical devices in Italy is an attempt to 
achieve a higher level of harmonization nationwide as to methods of assessing and 
appraising medical technologies. Although this is an important step towards the 
formal recognition of economic evaluation analysis in the decision making process, it 
is too early to evaluate its impact on the Italian NHS.  
 
,Q)UDQFHWKHJUHDWHVWDWWHQWLRQLVJLYHQWRWKH³DGGHGWKHUDSHXWLFYDOXH´ (the ASMR) 
of new drugs, which forms the basis for price negotiation. Economic evaluation is 
only used as background information in some instances. The French approach is quite 
similar to that in Germany. In these two countries there is some reluctance to be too 
prescriptive about how the benefits of health care are valued, or any suggestion of a 
µWKUHVKROG¶RIFRVW-effectiveness that is deemed acceptable. Rather, these assessments 
are left to health professionals on the expert committees that have been established to 
determine the level of benefit from new technologies. One consequence of this is a 
reduction in the level of transparency, which is consistent with the Napoleonic 
administrative tradition in France.   
    
Use of HTA and economic evaluation in decision-making 
Finally, culture and values also influence the use of economic evaluation in decision-
making. Across the 5 EU countries, only in the UK is there explicit rationing of 
healthcare based on cost-utility analysis. In France and Germany, the emphasis is on 
using evaluations to restrict the price paid by the health insurance system, whilst still 
making most therapies available. Up to now, in Italy and Spain, the fragmentation in 
the organization of economic evaluation across the regions translates to some extent 
into fragmentation of decision-making. Although for drugs, in Italy there is national 
price negotiation and in Spain a consortium of hospital pharmacists (called Genesis) 
has been conducting economic evaluation, predominantly in 2 of the 17 regions. 
[19,20] Also, for medical devices, the new Italian HTA programme  - if successful- 
would replace the current fragmentation of the decision-making with a harmonized 
process centrally coordinated by the MoH. [11] 
There are also differences in the transparency of the process of translating economic 
evaluation results into decisions and the general involvement of key stakeholders. 
Consistent with the Anglo-American administrative tradition, the reports produced by 
NICE in England are the most transparent among the 5 EU countries and are subject 
to the most comment by stakeholders, including the possibility of appeals against the 
recommendations. 
Discussion 
From the discussion above it appears that there is a fairly strong case to argue that 
culture, values and institutional context have an influence on the use of HTA and 
economic evaluation in health care, either directly, or indirectly through the impact on 
the organization of the health care system. Therefore, this observation may be useful 
both in explaining the different approaches to the use of economic evaluation between 
countries and in determining the most appropriate use of economic evaluation for 
other countries yet to adopt the approach.  
For example, this framework could be used to determine the way forward for the US, 
a country which is traditionally a low user of economic evaluation in health care. Of 
the five European countries studied, the US health care system is probably closest to 
the social insurance system existing in Germany, which is also a relatively low user of 
economic evaluation. However, given that the US places a greater emphasis on 
personal responsibility and less emphasis on equity, there is a lower appetite for any 
kind of collective action (in health care), whereas some level of collective action is 
required in order to operate a social health insurance system. Nevertheless, both 
countries are alike in eschewing the notion of a fixed budget for health care and 
explicit rationing, although of course there is some form of rationing in all health care 
systems.  
Therefore, in the US we might expect the US to use economic evaluation to influence 
the prices of health technologies, as is the case in France and Germany for drugs. 
Neumann and Saret point out that the US has led the way in payment reform [21] 
Why not let economic evaluation be a consideration in payment determination? 
Sorenson et al (2015) argue that prospective payments to hospitals (i.e. DRGs) 
represent an excellent opportunity for using economic evaluation to encourage the 
adoption of some new technologies, whilst deterring others. However, in most 
countries that use DRGs, this opportunity is not seized when reviewing payment rates. 
[22] Again, this approach has the advantage that it does not involve explicit rationing. 
It is merely giving greater financial rewards in situations where there are new cost-
effective technologies. Hospitals and physicians can then choose whether to respond 
to these incentives or not, and whether to negotiate more favourable prices with 
technology manufacturers. There has already been a growing trend for hospitals and 
other health care institutions in the US to be more critical of the high cost of some 
new technologies and to insist on price reductions, given the pressures on their 
budgets [23]  
In addition, given the high emphasis placed on personal responsibility, one might 
expect the US to use economic evaluation to help determine the level of patient 
copayments. There is some evidence of this, with one private health plan (Premera) 
establishing a value-based formulary, incorporating lower copays for drugs that are 
considered to be cost-effective and higher copays for those that are not. [24] 
However, although the framework set out here can provide a convincing explanation 
of the attitude towards the economic evaluation in a given country, key events can 
also bring about changes in this respect. For example, the crisis concerning a drug 
called Mediator in France, led to calls for greater transparency in decision-making by 
the HAS (de Pouvourville 2010, Drummond et al, 2014). One impact of this was the 
decision to insist on an economic evaluation as background information in cases 
where the manufacturer of a drug feels that the product should be awarded an ASMR 
of III or above. In addition, concerns over the refusal of NICE to recommend the use 
of some cancer drugs, led to a departure from the principle that all QALYs are valued 
HTXDOO\8QGHUWKHµHQGRIOLIH¶JXLGDQFHWKHDSSUDLVDOFRPPLWWHHFDQYDOXHµHQGRI
OLIH4$/<V¶DVEHing higher, effectively giving a priority for treating more serious or 
life-threatening conditions. 
In conclusion, if the approach to economic evaluation in health care is dependent on 
FXOWXUHYDOXHVDQGLQVWLWXWLRQDOFRQWH[WWKHUHFDQEHQRµRQHVL]HILWVDOO¶DSSURDFK
that is suitable in all countries. We believe that this conclusion should inform the 
increasing number of initiatives to harmonize or even standardize the methods and 
uses of economic evaluation across the EU and beyond. The framework set above 
could help shape these initiatives by helping each country determine which approach 
will best suit its circumstances. 
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